Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Recruiting now · Phase 2

Conditions studied: Metastatic Non-small Cell Lung Cancer

In brief

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.

Key facts

Study ID

NCT04410796

Run by

Memorial Sloan Kettering Cancer Center

People needed

571

Starts

2020-05-28

Expected to finish

2027-05-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Washington (Data Collection Only) — Seattle, Washington, United States (enrolling)
• MD ANDERSON CANCER CENTER (Data Collection Only) — Houston, Texas, United States (enrolling)
• UC Davis Cancer Center (Data Collection Only) — Sacramento, California, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• John Hopkins Medical Center — Baltimore, Maryland, United States (enrolling)
• Massachusetts General Hospital (Data Collection Only) — Boston, Massachusetts, United States (enrolling)
• Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey, United States (enrolling)
• Hackensack Meridian Health — Hackensack, New Jersey, United States (enrolling)
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey, United States (enrolling)
• Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey, United States (enrolling)
• Memorial Sloan Kettering Commack (Limited protocol activities) — Commack, New York, United States (enrolling)
• Memorial Sloan Kettering Westchester (Limited protocol activities) — Harrison, New York, United States (enrolling)
• New York University — New York, New York, United States (enrolling)
• Memorial Sloan Kettering Cancer Center (All protocol activities) — New York, New York, United States (enrolling)
• Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• University of California San Francisco — San Francisco, California, United States
• Columbia University (Data Collection Only) — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.